Theralase Technologies Inc.

Equities

TLT

CA88337V1004

Advanced Medical Equipment & Technology

Delayed Toronto S.E. 09:40:28 2024-03-28 am EDT 5-day change 1st Jan Change
0.165 CAD 0.00% Intraday chart for Theralase Technologies Inc. -5.71% -5.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Theralase Technologies Donates Cool Laser Therapy Technology to Aid in R&D of Treatment for Parkinson's Disease MT
Theralase Technologies Closes C$1.2-Million Private Placement of Share Units MT
Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding CI
Theralase Technologies Provides Update on Phase II Bladder Cancer Clinical Study MT
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study CI
Theralase Technologies Raises C$1.17 Million in a Private Placement of Share Units MT
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding CI
Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units MT
Theralase Technologies Inc. announced that it expects to receive CAD 1.5 million in funding CI
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study CI
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study CI
Theralase Technologies Inc. Files US Patent for Enhanced Immunotherapy CI
Theralase®? Technologies Inc. Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer CI
Theralase Technologies Inc. announced that it has received CAD 0.46 million in funding CI
Theralase Technologies First-Half Loss Narrows Even as Revenue Declined by 23% MT
Theralase Technologies Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Theralase Closes Non-Brokered Private Placement Equity Financing MT
Theralase Technologies Inc. announced that it has received CAD 1.2 million in funding CI
Theralase Technologies Inc. Announces Appointment of Kaouthar Lbiati as Independent Director CI
Theralase Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Theralase Re-appointed Founder Roger DuMoulin-White as President and CEO As OSC Order Has Expired MT
Theralase Technologies Inc. Announces Chief Executive Officer Changes CI
Theralase® Provides Update on Phase II Bladder Cancer Study CI
Chart Theralase Technologies Inc.
More charts
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.165 CAD
Average target price
0.8 CAD
Spread / Average Target
+384.85%
Consensus